<p>BioNTech SE（纳斯达克代码：BNTX - 获取免费报告）在周二的交易中出现了异常高的交易量。大约有 1,330,327 股在交易中易手，比前一交易日的 930,600 股增加了 43%。该股最后交易价格为 116.20 美元，之前收盘价为 113.10 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>4 个理由说明辉瑞可能是你不能错过的价值投资</li>
</ul>
<p>BNTX 最近成为几份分析师报告的主题。华尔街 Zen 在周五的研究报告中将 BioNTech 的评级从 “持有” 下调至 “卖出”。摩根士丹利在周二的研究报告中将 BioNTech 的目标价从 140.00 美元下调至 132.00 美元，并对该股给予 “增持” 评级。Canaccord Genuity Group 在 3 月 11 日的研究报告中重申了对 BioNTech 的 “买入” 评级，并设定了 171.44 美元的目标价。花旗集团在 5 月 6 日的研究报告中重申了对 BioNTech 的 “买入” 评级，并将目标价从 145.00 美元下调至 140.00 美元。最后，摩根大通在 5 月 22 日的研究报告中将 BioNTech 的目标价从 120.00 美元下调至 116.00 美元，并对该公司给予 “中性” 评级。一位投资分析师对该股给予了卖出评级，四位分析师给予了持有评级，十三位分析师给予了买入评级，还有一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 139.14 美元。</p>
<p><strong>查看我们最新的 BioNTech 股票报告</strong></p>
<h2>BioNTech 股票表现</h2>
<ul>
<li>Moderna 因第二季度收益下滑而下跌，但能否因空头回补而反弹？</li>
</ul>
<p>该公司的 50 日简单移动平均线为 97.78 美元，200 日简单移动平均线为 108.21 美元。公司的速动比率为 7.21，流动比率为 7.33，债务股本比率为 0.01。该公司的市值为 283.8 亿美元，市盈率为-56.22，贝塔值为 1.35。</p>
<p>BioNTech（纳斯达克代码：BNTX - 获取免费报告）在 3 月 10 日星期一发布了其财报。该公司报告本季度每股收益为 1.08 美元，超出分析师共识预期的 0.38 美元，超出幅度为 0.70 美元。BioNTech 的股本回报率为-2.35%，净利润率为-15.16%。该公司本季度的收入为 11.9 亿美元，而分析师预期为 12.4 亿美元。在去年同期，该公司每股收益为 1.90 美元。该公司的季度收入同比下降了 19.5%。平均而言，卖方分析师预测 BioNTech SE 在当前财政年度将发布-3.88 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>Novavax 因收益不及预期而暴跌：是下跌刀还是买入机会？</li>
</ul>
<p>大型投资者最近对该股的持仓进行了调整。纽约梅隆银行在第四季度将其在 BioNTech 的持股增加了 4.3%。纽约梅隆银行目前拥有 3,677 股该公司的股票，价值 419,000 美元，此前在上个季度又购买了 150 股。C2P Capital Advisory Group LLC 以 Prosperity Capital Advisors 名义在第四季度购买了 BioNTech 的新头寸，价值约为 1,118,000 美元。Van ECK Associates Corp 在第四季度将其在 BioNTech 的持股增加了 25.1%。Van ECK Associates Corp 目前拥有 118,418 股该公司的股票，价值 13,493,000 美元，此前在上个季度又购买了 23,733 股。查尔斯·施瓦布投资管理公司在第四季度将其在 BioNTech 的持股增加了 39.8%。查尔斯·施瓦布投资管理公司目前拥有 187,355 股该公司的股票，价值 21,349,000 美元，此前在上个季度又购买了 53,319 股。最后，abrdn plc 在第四季度将其在 BioNTech 的持股增加了 70.7%。abrdn plc 目前拥有 385,668 股该公司的股票，价值 43,947,000 美元，此前在上个季度又购买了 159,676 股。15.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>BioNTech 公司简介</h2>
<p>（获取免费报告）</p>
<p>BioNTech SE 是一家生物技术公司，开发和商业化用于癌症和其他传染病的免疫疗法。该公司正在开发 FixVac 产品候选药物，包括 BNT111，该药物正在进行针对晚期黑色素瘤的二期临床试验；BNT112 正在进行针对前列腺癌的 I/IIa 期临床试验；BNT113 正在进行针对 HPV 16+ 头颈癌的二期临床试验；BNT114 用于治疗三阴性乳腺癌；BNT115 正在进行针对卵巢癌的 I 期临床试验；BNT116 正在进行针对非小细胞肺癌的 I 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 BioNTech</li>
<li>关于 Markup 计算器</li>
<li>博通收益预览：AVGO 股票接近历史高点</li>
<li>什么是特别股息？</li>
<li>3 个理由说明亚马逊可能是 6 月最佳科技表现者</li>
<li>投资便士股票需要知道的事项</li>
<li>Palantir 因政府交易飙升，估值争论仍在继续</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 BioNTech 吗？</h2>
<p>在考虑 BioNTech 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 BioNTech 并不在名单上。</p>
<p>虽然 BioNTech 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

BNTX

<p>BioNTech（纳斯达克代码：BNTX）交易量显著增加，约有 133 万股交易，较前一交易日上涨 43%。股价从 113.10 美元上涨至 116.20 美元。分析师的评级意见不一，其中一项为卖出，四项为持有，十三项为买入。共识目标价为 139.14 美元。BioNTech 报告的季度每股收益为 1.08 美元，超出预期，但营收同比下降 19.5%。机构投资者已增加对该公司的持股，该公司专注于开发癌症和传染病的免疫疗法</p>

<p>Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 1,330,327 shares changed hands during trading, an increase of 43% from the previous session's volume of 930,600 shares.The stock last traded at $116.20 and had previously closed at $113.10.</p>
<div class="lb-trans"><p>BioNTech SE（纳斯达克代码：BNTX - 获取免费报告）在周二的交易中出现了异常高的交易量。大约有 1,330,327 股在交易中易手，比前一交易日的 930,600 股增加了 43%。该股最后交易价格为 116.20 美元，之前收盘价为 113.10 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>4 Reasons Pfizer Could Be a Value Play You Can't Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>4 个理由说明辉瑞可能是你不能错过的价值投资</li>
</ul>
</div><p>BNTX has been the topic of several recent analyst reports. Wall Street Zen cut BioNTech from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Friday. Morgan Stanley dropped their price objective on BioNTech from $140.00 to $132.00 and set an &#34;overweight&#34; rating on the stock in a research note on Tuesday, May 6th. Canaccord Genuity Group restated a &#34;buy&#34; rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Citigroup reaffirmed a &#34;buy&#34; rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Finally, JPMorgan Chase &amp; Co. decreased their target price on BioNTech from $120.00 to $116.00 and set a &#34;neutral&#34; rating for the company in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $139.14.</p>
<div class="lb-trans"><p>BNTX 最近成为几份分析师报告的主题。华尔街 Zen 在周五的研究报告中将 BioNTech 的评级从 “持有” 下调至 “卖出”。摩根士丹利在周二的研究报告中将 BioNTech 的目标价从 140.00 美元下调至 132.00 美元，并对该股给予 “增持” 评级。Canaccord Genuity Group 在 3 月 11 日的研究报告中重申了对 BioNTech 的 “买入” 评级，并设定了 171.44 美元的目标价。花旗集团在 5 月 6 日的研究报告中重申了对 BioNTech 的 “买入” 评级，并将目标价从 145.00 美元下调至 140.00 美元。最后，摩根大通在 5 月 22 日的研究报告中将 BioNTech 的目标价从 120.00 美元下调至 116.00 美元，并对该公司给予 “中性” 评级。一位投资分析师对该股给予了卖出评级，四位分析师给予了持有评级，十三位分析师给予了买入评级，还有一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 139.14 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on BioNTech</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 BioNTech 股票报告</strong></p>
</div><h2>BioNTech Stock Performance</h2>
<div class="lb-trans"><h2>BioNTech 股票表现</h2>
</div><ul>
<li>Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 因第二季度收益下滑而下跌，但能否因空头回补而反弹？</li>
</ul>
</div><p>The business has a fifty day simple moving average of $97.78 and a 200-day simple moving average of $108.21. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market cap of $28.38 billion, a P/E ratio of -56.22 and a beta of 1.35.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 97.78 美元，200 日简单移动平均线为 108.21 美元。公司的速动比率为 7.21，流动比率为 7.33，债务股本比率为 0.01。该公司的市值为 283.8 亿美元，市盈率为-56.22，贝塔值为 1.35。</p>
</div><p>BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same period in the prior year, the firm posted $1.90 earnings per share. The company's quarterly revenue was down 19.5% on a year-over-year basis. On average, sell-side analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>BioNTech（纳斯达克代码：BNTX - 获取免费报告）在 3 月 10 日星期一发布了其财报。该公司报告本季度每股收益为 1.08 美元，超出分析师共识预期的 0.38 美元，超出幅度为 0.70 美元。BioNTech 的股本回报率为-2.35%，净利润率为-15.16%。该公司本季度的收入为 11.9 亿美元，而分析师预期为 12.4 亿美元。在去年同期，该公司每股收益为 1.90 美元。该公司的季度收入同比下降了 19.5%。平均而言，卖方分析师预测 BioNTech SE 在当前财政年度将发布-3.88 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?</li>
</ul>
<div class="lb-trans"><ul>
<li>Novavax 因收益不及预期而暴跌：是下跌刀还是买入机会？</li>
</ul>
</div><p>Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after purchasing an additional 150 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in BioNTech in the 4th quarter worth approximately $1,118,000. Van ECK Associates Corp lifted its holdings in BioNTech by 25.1% in the 4th quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock worth $13,493,000 after purchasing an additional 23,733 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in BioNTech by 39.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock worth $21,349,000 after purchasing an additional 53,319 shares in the last quarter. Finally, abrdn plc lifted its holdings in BioNTech by 70.7% in the 4th quarter. abrdn plc now owns 385,668 shares of the company's stock worth $43,947,000 after purchasing an additional 159,676 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近对该股的持仓进行了调整。纽约梅隆银行在第四季度将其在 BioNTech 的持股增加了 4.3%。纽约梅隆银行目前拥有 3,677 股该公司的股票，价值 419,000 美元，此前在上个季度又购买了 150 股。C2P Capital Advisory Group LLC 以 Prosperity Capital Advisors 名义在第四季度购买了 BioNTech 的新头寸，价值约为 1,118,000 美元。Van ECK Associates Corp 在第四季度将其在 BioNTech 的持股增加了 25.1%。Van ECK Associates Corp 目前拥有 118,418 股该公司的股票，价值 13,493,000 美元，此前在上个季度又购买了 23,733 股。查尔斯·施瓦布投资管理公司在第四季度将其在 BioNTech 的持股增加了 39.8%。查尔斯·施瓦布投资管理公司目前拥有 187,355 股该公司的股票，价值 21,349,000 美元，此前在上个季度又购买了 53,319 股。最后，abrdn plc 在第四季度将其在 BioNTech 的持股增加了 70.7%。abrdn plc 目前拥有 385,668 股该公司的股票，价值 43,947,000 美元，此前在上个季度又购买了 159,676 股。15.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>BioNTech Company Profile</h2>
<div class="lb-trans"><h2>BioNTech 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.</p>
<div class="lb-trans"><p>BioNTech SE 是一家生物技术公司，开发和商业化用于癌症和其他传染病的免疫疗法。该公司正在开发 FixVac 产品候选药物，包括 BNT111，该药物正在进行针对晚期黑色素瘤的二期临床试验；BNT112 正在进行针对前列腺癌的 I/IIa 期临床试验；BNT113 正在进行针对 HPV 16+ 头颈癌的二期临床试验；BNT114 用于治疗三阴性乳腺癌；BNT115 正在进行针对卵巢癌的 I 期临床试验；BNT116 正在进行针对非小细胞肺癌的 I 期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than BioNTech</li>
<li>About the Markup Calculator</li>
<li>Broadcom Earnings Preview: AVGO Stock Near Record Highs</li>
<li>What is a Special Dividend?</li>
<li>3 Reasons Amazon Could Be the Best Tech Performer in June</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>Palantir Soars on Government Deals as Valuation Debate Lingers</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 BioNTech</li>
<li>关于 Markup 计算器</li>
<li>博通收益预览：AVGO 股票接近历史高点</li>
<li>什么是特别股息？</li>
<li>3 个理由说明亚马逊可能是 6 月最佳科技表现者</li>
<li>投资便士股票需要知道的事项</li>
<li>Palantir 因政府交易飙升，估值争论仍在继续</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioNTech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BioNTech 吗？</h2>
</div><p>Before you consider BioNTech, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 BioNTech 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 BioNTech 并不在名单上。</p>
</div><p>While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioNTech 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

BioNTech（NASDAQ:BNTX）交易量大幅增加 - 原因如下